Leukapheresis Market is projected to reach US$ 93 million by 2027
The global Leukapheresis market gathered revenue around USD 62 million in 2020 and market is set to grow USD 93 million by the end of 2027 and is estimated to expand at a modest CAGR of 9.2% during the prediction period 2021 to 2027. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Leukapheresis market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Leukapheresis market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Leukapheresis market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Opportunity: Leukapheresis for pediatric patients
Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side-effects and risks of conventional treatments such as chemotherapy for children. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed as well as emerging markets.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Leukapheresis Market are:
Some prominent players in The leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
The research report categorizes the market into the following segments and subsegments:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Leukapheresis Market, By Type
7.1. Leukapheresis Market, By Type, 2021-2027
7.1.1. Leukapheresis Disposables
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Leukapheresis Devices
7.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Leukapheresis Market, By Application
8.1. Leukapheresis Market, By Application, 2021-2027
8.1.1. Research Applications
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Therapeutic Applications
8.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Leukapheresis Market, By End User
9.1. Leukapheresis Market, By End User, 2021-2027
9.1.1. Blood Component Providers & Blood Centers
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Academic & Research Institutes
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Pharmaceutical & Biotechnology Companies
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Hospital & Transfusion Centers
9.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Leukapheresis Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Type (2016-2027)
10.1.2. Market Revenue and Forecast, By Application (2016-2027)
10.1.3. Market Revenue and Forecast, By End User (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Type (2016-2027)
10.1.4.2. Market Revenue and Forecast, By Application (2016-2027)
10.1.4.3. Market Revenue and Forecast, By End User (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Type (2016-2027)
10.1.5.2. Market Revenue and Forecast, By Application (2016-2027)
10.1.5.3. Market Revenue and Forecast, By End User (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Type (2016-2027)
10.2.2. Market Revenue and Forecast, By Application (2016-2027)
10.2.3. Market Revenue and Forecast, By End User (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Type (2016-2027)
10.2.4.2. Market Revenue and Forecast, By Application (2016-2027)
10.2.4.3. Market Revenue and Forecast, By End User (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Type (2016-2027)
10.2.5.2. Market Revenue and Forecast, By Application (2016-2027)
10.2.5.3. Market Revenue and Forecast, By End User (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Type (2016-2027)
10.2.6.2. Market Revenue and Forecast, By Application (2016-2027)
10.2.6.3. Market Revenue and Forecast, By End User (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Type (2016-2027)
10.2.7.2. Market Revenue and Forecast, By Application (2016-2027)
10.2.7.3. Market Revenue and Forecast, By End User (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Type (2016-2027)
10.3.2. Market Revenue and Forecast, By Application (2016-2027)
10.3.3. Market Revenue and Forecast, By End User (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Type (2016-2027)
10.3.4.2. Market Revenue and Forecast, By Application (2016-2027)
10.3.4.3. Market Revenue and Forecast, By End User (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Type (2016-2027)
10.3.5.2. Market Revenue and Forecast, By Application (2016-2027)
10.3.5.3. Market Revenue and Forecast, By End User (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Type (2016-2027)
10.3.6.2. Market Revenue and Forecast, By Application (2016-2027)
10.3.6.3. Market Revenue and Forecast, By End User (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Type (2016-2027)
10.3.7.2. Market Revenue and Forecast, By Application (2016-2027)
10.3.7.3. Market Revenue and Forecast, By End User (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Type (2016-2027)
10.4.2. Market Revenue and Forecast, By Application (2016-2027)
10.4.3. Market Revenue and Forecast, By End User (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Type (2016-2027)
10.4.4.2. Market Revenue and Forecast, By Application (2016-2027)
10.4.4.3. Market Revenue and Forecast, By End User (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Type (2016-2027)
10.4.5.2. Market Revenue and Forecast, By Application (2016-2027)
10.4.5.3. Market Revenue and Forecast, By End User (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Type (2016-2027)
10.4.6.2. Market Revenue and Forecast, By Application (2016-2027)
10.4.6.3. Market Revenue and Forecast, By End User (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Type (2016-2027)
10.4.7.2. Market Revenue and Forecast, By Application (2016-2027)
10.4.7.3. Market Revenue and Forecast, By End User (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Type (2016-2027)
10.5.2. Market Revenue and Forecast, By Application (2016-2027)
10.5.3. Market Revenue and Forecast, By End User (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Type (2016-2027)
10.5.4.2. Market Revenue and Forecast, By Application (2016-2027)
10.5.4.3. Market Revenue and Forecast, By End User (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Type (2016-2027)
10.5.5.2. Market Revenue and Forecast, By Application (2016-2027)
10.5.5.3. Market Revenue and Forecast, By End User (2016-2027)
Chapter 11. Company Profiles
11.1. Asahi Kasei Medical Co. Ltd. (Japan)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Fresenius SE & Co. KGaA (Germany)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Haemonetics Corporation (US)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Terumo BCT, Inc. (US)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Macopharma SA (France)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Miltenyi Biotec (Germany)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Guangzhou Daji Medical Science Technology Co. Ltd. (China)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. MEDICA S.p.A (Italy)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. PuriBlood Medical Co. Ltd. (Taiwan)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Beijing ZKSK Technology Co. Ltd. (China)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Charles River Laboratories (US)
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. AllCells, LLC (US)
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. StemExpress, LLC. (US)
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. Caltag Medsystems Limited (UK)
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Lonza Group AG (Switzerland)
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. ZenBio (US)
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Precision for Medicine (US)
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. BioIVT (US)
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Discovery Life Sciences (US)
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives
11.20. Intelligent Tissue Group (US)
11.20.1. Company Overview
11.20.2. Product Offerings
11.20.3. Financial Performance
11.20.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers